Side effects of Wegovy in pill form: what the evidence shows

What side effects did people actually experience in the tablet trial?

The OASIS 4 trial ran for 64 weeks and enrolled 307 adults with obesity or overweight alongside at least one weight-related condition. The oral semaglutide group reported gastrointestinal symptoms at a rate of 74%, against 42% in the placebo arm, a meaningful difference, though the majority of cases were recorded as mild to moderate and transient. The most frequently reported effects were nausea, diarrhoea, vomiting, constipation and burping. Fatigue and headache were also noted, and some people experienced reflux or indigestion, particularly around the time the dose was increased.

Symptoms tended to cluster around the start of each new dose step rather than running continuously throughout treatment. For most participants they improved within days to a couple of weeks. If you'd like a fuller breakdown of how the GI profile compares to what's reported for semaglutide tablets and the side effects associated with them generally, our dedicated guide to semaglutide tablet side effects in the context of weight loss goes into more detail on that pattern.

It's worth knowing that the tablet's absorption mechanism (semaglutide co-formulated with SNAC to enable uptake through the stomach lining) means GI effects can be more pronounced if the medicine is taken with food, a large volume of water, or too close to other oral medicines. The instructions are specific for a reason: first thing in the morning, on an empty stomach, with no more than about 120ml of plain water, waiting at least 30 minutes before eating or drinking anything else. Getting this right from the first dose gives your digestive system the easiest possible introduction to treatment.

Which symptoms genuinely need medical attention right away?

Most people reading this are looking for reassurance, and the honest answer is that the vast majority of side effects people notice with the Wegovy pill are unpleasant rather than dangerous. That said, there are specific signs that require prompt medical help, and knowing them matters.

Severe, persistent stomach pain that radiates to the back (with or without vomiting) should not be waited out. This pattern can indicate acute pancreatitis, which the MHRA flagged formally in a Drug Safety Update in January 2026 as a known infrequent but serious risk with GLP-1 medicines. Stop treatment and contact a healthcare professional or NHS 111 immediately if this occurs.

Other symptoms that warrant prompt attention include signs of a severe allergic reaction (swelling of the face, lips or throat, difficulty breathing, widespread rash), symptoms of significant dehydration from prolonged vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), and any sudden changes in vision if you have diabetes. Gallbladder problems have also been reported with GLP-1 medicines: sharp pain in the upper right abdomen, fever or yellowing of the skin or eyes should be assessed medically.

If you're uncertain whether what you're experiencing requires action, the safest course is to contact your prescriber or call NHS 111. Our support team is available seven days a week for aftercare queries too.

Does how you take the tablet change the side-effect experience?

Yes, meaningfully so. The administration rules for the oral Wegovy tablet are stricter than for most daily medicines, and breaking them doesn't just reduce effectiveness; it can make side effects worse. Taking the tablet with food, coffee, or a second pill at the same time increases direct gastric exposure to semaglutide in a way that heightens nausea and gut irritability for some people.

The practical upside is that the tablet requires no refrigeration, which makes it easier to build into a consistent morning routine compared to the injectable forms. Many people find it helps to leave the pack next to their phone or alarm, somewhere visible before the kettle is switched on.

Dose titration also plays a significant role. Treatment begins at 1.5mg and steps up through 4mg and 9mg before reaching the 25mg maintenance dose, with a minimum of one month at each level. That gradual ramp exists precisely to give the gastrointestinal tract time to adapt. Rushing titration is associated with more severe side effects that oral semaglutide can produce. Your prescriber makes those decisions; the schedule is not something to adjust independently. For a broader look at how the tablet fits into treatment, our page on oral semaglutide tablets covers the licensed context in full.

How are side effects monitored, and what should you do if you experience them?

Clinical oversight doesn't stop at the point of dispensing. Before every repeat supply, our prescribers review your progress, including any side effects that semaglutide pills can cause that you've reported. That review is carried out by a real clinician, not automated, our clinical team oversees every prescription personally.

If a side effect feels manageable but persistent, logging it and raising it at your next review is often the right approach. If something worries you sooner, our aftercare team is reachable seven days a week. For anything urgent (chest pain, severe abdominal pain, difficulty breathing) contact emergency services or go to A&E directly rather than waiting for an online response.

The MHRA's Yellow Card scheme lets patients and healthcare professionals report suspected side effects directly to the regulator. This is especially relevant for a medicine as recently approved as the Wegovy tablet (UK approval: June 2026, making the UK the first in Europe to license it for weight management), where the real-world safety profile is still being built up through post-marketing surveillance. Reporting contributes to that process and is entirely voluntary.

If you'd like to discuss your personal suitability and what to expect from treatment before committing to anything, our prescribers cover side effects in detail during the consultation. Check your eligibility to begin a free clinical assessment.